Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Baoying Huang and Wenjie Tan.
Baoying Huang
Connection Strength
5.226
Wenjie Tan
  1. Real-time reverse transcription-polymerase chain reaction assay panel for the detection of severe acute respiratory syndrome coronavirus 2 and its variants. Chin Med J (Engl). 2021 Aug 16; 134(17):2048-2053.
    View in: PubMed
    Score: 0.241
  2. Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study. Virol Sin. 2021 10; 36(5):1088-1092.
    View in: PubMed
    Score: 0.238
  3. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021 05 31; 6(1):213.
    View in: PubMed
    Score: 0.237
  4. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2. Lancet Microbe. 2021 Jul; 2(7):e285.
    View in: PubMed
    Score: 0.235
  5. Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China. Protein Cell. 2021 01; 12(1):4-6.
    View in: PubMed
    Score: 0.230
  6. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. Biosaf Health. 2020 Dec; 2(4):226-231.
    View in: PubMed
    Score: 0.225
  7. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat Commun. 2020 08 06; 11(1):3910.
    View in: PubMed
    Score: 0.224
  8. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine. 2020 Aug; 58:102890.
    View in: PubMed
    Score: 0.223
  9. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 02 22; 395(10224):565-574.
    View in: PubMed
    Score: 0.216
  10. Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res. 2020 01; 173:104646.
    View in: PubMed
    Score: 0.213
  11. High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019 06 15; 93(12).
    View in: PubMed
    Score: 0.206
  12. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine. 2019 04 03; 37(15):2122-2130.
    View in: PubMed
    Score: 0.203
  13. Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus. Virol Sin. 2018 Oct; 33(5):453-455.
    View in: PubMed
    Score: 0.198
  14. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient. J Infect Dis. 2018 09 08; 218(8):1249-1260.
    View in: PubMed
    Score: 0.196
  15. The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens. Vaccine. 2018 06 18; 36(26):3740-3746.
    View in: PubMed
    Score: 0.192
  16. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018 Apr 04; 7(1):60.
    View in: PubMed
    Score: 0.190
  17. Dr. Chi-Ming Chu: Respected founder of molecular virology and pioneer of biologicals in China. Protein Cell. 2017 09; 8(9):629-633.
    View in: PubMed
    Score: 0.183
  18. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg Microbes Infect. 2017 Jun 28; 6(6):e60.
    View in: PubMed
    Score: 0.181
  19. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg Microbes Infect. 2017 May 24; 6(5):e37.
    View in: PubMed
    Score: 0.179
  20. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. 2013 Dec; 4(12):951-61.
    View in: PubMed
    Score: 0.141
  21. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. J Enzyme Inhib Med Chem. 2021 Dec; 36(1):497-503.
    View in: PubMed
    Score: 0.061
  22. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 05 29; 6(1):212.
    View in: PubMed
    Score: 0.059
  23. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021 Apr 28; 134(11):1289-1298.
    View in: PubMed
    Score: 0.059
  24. Publisher Correction: A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat Commun. 2021 Apr 15; 12(1):2355.
    View in: PubMed
    Score: 0.059
  25. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice. Cell Mol Immunol. 2021 03; 18(3):749-751.
    View in: PubMed
    Score: 0.058
  26. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat Commun. 2021 02 03; 12(1):776.
    View in: PubMed
    Score: 0.058
  27. Reply to "Novaferon, treatment in COVID-19 patients". Int J Infect Dis. 2021 02; 103:336-337.
    View in: PubMed
    Score: 0.057
  28. Comparative Transcriptome Analysis Reveals the Intensive Early Stage Responses of Host Cells to SARS-CoV-2 Infection. Front Microbiol. 2020; 11:593857.
    View in: PubMed
    Score: 0.057
  29. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 01; 21(1):39-51.
    View in: PubMed
    Score: 0.057
  30. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020 09 04; 11(1):4417.
    View in: PubMed
    Score: 0.056
  31. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. Int J Infect Dis. 2020 Oct; 99:84-91.
    View in: PubMed
    Score: 0.056
  32. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 07 28; 71(15):732-739.
    View in: PubMed
    Score: 0.056
  33. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020 08 06; 182(3):713-721.e9.
    View in: PubMed
    Score: 0.055
  34. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 07; 583(7818):830-833.
    View in: PubMed
    Score: 0.055
  35. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020 05 29; 368(6494):1016-1020.
    View in: PubMed
    Score: 0.055
  36. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med. 2020 Mar; 3(1):93-97.
    View in: PubMed
    Score: 0.055
  37. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020 03 11; 27(3):325-328.
    View in: PubMed
    Score: 0.054
  38. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 02 20; 382(8):727-733.
    View in: PubMed
    Score: 0.054
  39. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Nat Commun. 2019 07 11; 10(1):3068.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.